Alexion Pharmaceuticals’ ravulizumab has expanded the range of indications for treating a rare complement-mediated disease.
Autoimmune Diseases
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases
AstraZeneca + Alexion = Rescue of Both Companies
Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.